AKBA

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a Cambridge, Massachusetts-based biopharmaceutical company founded in 2007 that specializes in developing and commercializing treatments for patients with kidney diseases. The company has evolved from a pure development-stage biotechnology firm into a commercial-stage company with marketed products and a robust pipeline. Akebia's primary focus centers on addressing the significant unmet medical needs in chronic kidney disease (CKD), particularly anemia management in dialysis and non-dialysis patients. The company currently markets two approved therapies and has recently launched its flagship product Vafseo (vadadustat) in the United States after years of regulatory challenges.